These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34774637)

  • 21. Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts.
    Carrascosa JM; Vilarrasa E; Belinchón I; Herranz P; Crespo J; Guimerá F; Olveira A;
    Actas Dermosifiliogr; 2023 May; 114(5):392-401. PubMed ID: 36720362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
    Wong VW; Chan WK; Chitturi S; Chawla Y; Dan YY; Duseja A; Fan J; Goh KL; Hamaguchi M; Hashimoto E; Kim SU; Lesmana LA; Lin YC; Liu CJ; Ni YH; Sollano J; Wong SK; Wong GL; Chan HL; Farrell G
    J Gastroenterol Hepatol; 2018 Jan; 33(1):70-85. PubMed ID: 28670712
    [No Abstract]   [Full Text] [Related]  

  • 23. The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population.
    Sheng G; Peng N; Hu C; Zhong L; Zhong M; Zou Y
    Lipids Health Dis; 2021 May; 20(1):50. PubMed ID: 33993872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Liver diseases. Non-alcoholic fatty liver disease].
    Bernal Reyes R
    Rev Gastroenterol Mex; 2010 Aug; 75 Suppl 1():181-3. PubMed ID: 20959244
    [No Abstract]   [Full Text] [Related]  

  • 25. Saudi association for the study of liver diseases and transplantation position statement on the hepatology workforce in Saudi Arabia.
    Al-Judaibi B; Dokus MK; Al-Hamoudi W; Broering D; Mawardi M; AlMasri N; Aljawad M; Altraif IH; Abaalkhail F; Alqahtani SA
    Saudi J Gastroenterol; 2022; 28(2):101-107. PubMed ID: 35295066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.
    Middleton JP; Wiener RC; Barnes BH; Gurka MJ; DeBoer MD
    Clin Pediatr (Phila); 2014 Dec; 53(14):1318-25. PubMed ID: 24477713
    [No Abstract]   [Full Text] [Related]  

  • 27. [[113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Diagnosis and Management of Non-alcoholic Fatty Liver Diseases and Non-alcoholic Steatohepatitis: Current Concepts].
    Hashimoto E
    Nihon Naika Gakkai Zasshi; 2016 Sep; 105(9):1753-60. PubMed ID: 30169948
    [No Abstract]   [Full Text] [Related]  

  • 28. [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
    Maevskaya MV; Kotovskaya YV; Ivashkin VT; Tkacheva ON; Troshina EA; Shestakova MV; Breder VV; Geyvandova NI; Doshchitsin VL; Dudinskaya EN; Ershova EV; Kodzoeva KB; Komshilova KA; Korochanskaya NV; Mayorov AY; Mishina EE; Nadinskaya MY; Nikitin IG; Pogosova NV; Tarzimanova AI; Shamkhalova MS
    Ter Arkh; 2022 Feb; 94(2):216-253. PubMed ID: 36286746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparing for the NASH Epidemic: A Call to Action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Gastroenterology; 2021 Sep; 161(3):1030-1042.e8. PubMed ID: 34416976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correspondence: "A multisociety Delphi consensus statement on new fatty liver disease nomenclature".
    Wan KS; Chan WK; Yusoff MFM; Mustapha F; Rifin HM; Ratnam KKY; Ahmad NA
    Ann Hepatol; 2024; 29(4):101485. PubMed ID: 38403072
    [No Abstract]   [Full Text] [Related]  

  • 32. Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
    Alswat KA; Fallatah HI; Al-Judaibi B; Elsiesy HA; Al-Hamoudi WK; Qutub AN; Alturaify N; Al-Osaimi A
    Saudi Med J; 2019 Jun; 40(6):531-540. PubMed ID: 31219486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D Levels Are Inversely Associated with Liver Fat Content and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Middle-Aged and Elderly Population: The Shanghai Changfeng Study.
    Wang D; Lin H; Xia M; Aleteng Q; Li X; Ma H; Pan B; Gao J; Gao X
    PLoS One; 2016; 11(6):e0157515. PubMed ID: 27284686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    ; LaBrecque DR; Abbas Z; Anania F; Ferenci P; Khan AG; Goh KL; Hamid SS; Isakov V; Lizarzabal M; Peñaranda MM; Ramos JF; Sarin S; Stimac D; Thomson AB; Umar M; Krabshuis J; LeMair A;
    J Clin Gastroenterol; 2014 Jul; 48(6):467-73. PubMed ID: 24921212
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease.
    Rowe IA
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):66-72. PubMed ID: 29254617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease and the interface between primary and secondary care.
    Tsochatzis EA; Newsome PN
    Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):509-517. PubMed ID: 29893235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease.
    van Dijk AM; Schattenberg JM; Holleboom AG; Tushuizen ME
    United European Gastroenterol J; 2021 Oct; 9(8):903-909. PubMed ID: 34609086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 40. [Non-alcoholic fatty liver disease in type 2 diabetes: a joint statement of the Chilean Hepatology and Diabetology Societies].
    Arab JP; Castro L; Gómez PC; Vignolo P; Arrese M; Barrera F; Castro F; Díaz LA; Donoso A; Elgueta K; González K; González MI; Moreno M; Lazarte R; Poniachik J; Salman P; Valderas JP
    Rev Med Chil; 2021 Sep; 149(9):1360-1371. PubMed ID: 35319691
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.